A5029022002- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Drug-Induced Adverse Reactions
- SARS-CoV-2 and COVID-19 Research
- Mast cells and histamine
- Hemoglobinopathies and Related Disorders
- COVID-19 Clinical Research Studies
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Colorectal and Anal Carcinomas
- Galectins and Cancer Biology
- Pneumocystis jirovecii pneumonia detection and treatment
- Gastrointestinal Tumor Research and Treatment
- Parathyroid Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Parvovirus B19 Infection Studies
- Autoimmune Neurological Disorders and Treatments
- Analog and Mixed-Signal Circuit Design
- Helicobacter pylori-related gastroenterology studies
- Semiconductor materials and devices
- Kruppel-like factors research
- Amyloidosis: Diagnosis, Treatment, Outcomes
Universitat de València
2016-2025
INCLIVA Health Research Institute
2021-2025
Hospital Clínico Universitario de Valencia
2010-2023
Consejería de Salud y Consumo
2020
Immune effector cell-associated neurotoxicity syndrome (ICANS) is common after chimeric antigen receptor T-cell (CAR-T) therapy. Objective. This study aimed to assess the impact of preinfusion electroencephalography (EEG) abnormalities and EEG findings at ICANS onset for predicting risk severity in 56 adult patients with refractory lymphoma undergoing CAR-T Study design. EEGs were conducted time lymphodepleting chemotherapy shortly ICANS. Results. Twenty-eight (50%) developed a median 6 days...
Summary Standardized criteria of response to treatment and a unified definition resistance/intolerance hydroxycarbamide (HC) in essential thrombocythaemia (ET) have been proposed by the European LeukaemiaNet (ELN). We retrospectively evaluated such 166 ET patients treated with HC for median 4·5 years. Overall, 134 achieved complete clinicohaematological (CR) 25 partial response. Thirty‐three met at least one ELN defining resistance ( n = 15) or intolerance 21) HC. Fifteen cases developed...
ABSTRACT Introduction Current guidelines do not mandate CD19 tumor expression assessment before chimeric antigen receptor T‐cell (CAR‐T) therapy in large B‐cell lymphoma (LBCL) patients due to limitations of immunohistochemistry (IHC) or flow cytometry. Quantitative polymerase chain reaction (qPCR) offers a more sensitive alternative for detecting expression, with the primary advantage that mRNA can be easily extracted from paraffin‐embedded tissues. Methods & Results In our study, we...
Here we report the applicability of a protocol based on clinical conditions and risk factors (RFs) for managing 35 allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients who developed total 52 episodes respiratory viral infections (RVIs) caused by syncytial virus (RSV; n=19), human parainfluenza (HPIV; n=29), or both (n=4) over 2-year study period. Risk categories were classified as high (cat-1) when immunodeficiency scoring index was ≥3 and/or RFs ≥1 co-infective...
Abstract This retrospective study evaluated 66 patients diagnosed with relapsed and/or refractory mantle cell lymphoma (R/R MCL) treated ibrutinib in Spain routine clinical practice. At diagnosis, had a median age of 64.5 years, 63.6% presented intermediate/high sMIPI (simplified prognostic index for advanced-stage lymphoma), 24.5% the blastoid variant, and 55.6% Ki67 > 30%. Patients received 2 prior lines therapy (range 1–2; min–max 1–7). Overall response rate was 63.5%, 38.1% achieving...